Latest KFF Health News Stories
Pressure Builds To Cut Medicare Patients In On Prescription Deals
Medicare officials have been discussing a rule change that would give beneficiaries a share of the secretive fees and discounts that are negotiated for prescription drugs.
Study Gives Mixed Reviews On Laws To Equalize Cancer Patients’ Out-Of-Pocket Costs
Most states have laws that require that cancer patients who get their treatment orally rather than by infusion in a doctor’s office not pay more out-of-pocket. A new study finds that the impact of those laws is mixed.
Ohio’s Drug-Pricing Ballot Question Triggers Voter Confusion
Millions of dollars in campaign spending and a media blitz of advertisements muddy public understanding of Issue 2, the Drug Price Relief Act.
House Republicans Aim To Yank Tax Credits For Orphan Drugs
House Republicans want to repeal federal tax credits that have helped spur a boom in orphan drugs for rare diseases.
Timeline: Insulin Market Under Scrutiny
A flurry of federal and state probes have targeted insulin manufacturers and pharmacy benefit managers — middlemen in the prescription drug-pricing pipeline. Here, we connect the legal dots.
Flurry Of Federal And State Probes Target Insulin Drugmakers And Pharma Middlemen
Over the past two years, a powerful federal prosecutor and several state attorneys general have launched investigations related to diabetes drugs.
Desperate Quest For Herpes Cure Launched ‘Rogue’ Trial
Patients flocked to researcher who ignored usual patient protections, as university claimed ignorance.
Cascade of Costs Could Push New Gene Therapy Above $1 Million Per Patient
The costs of using a new class of cancer treatments include far more than the drug’s sticker price.
New Law Challenges ‘Evils’ Of Pharma Profits, California Governor Claims
Gov. Jerry Brown signed the measure, which takes effect next year and will require drug companies to publicly justify big price increases.
Eyes Fixed On California As Governor Ponders Inking Drug Price Transparency Bill
“If it gets signed by this governor, it’s going to send shock waves throughout the country,” one legislator says. Pharma has spent $16.8 million lobbying against this bill and other drug laws in California.
Más pacientes del Medicaid y presos podrán tratarse con una droga contra la hepatitis C
El tratamiento con una droga aprobada por la Administración de Drogas y Alimentos cuesta menos y cura la hepatitis C en alrededor de dos meses. Pacientes vulnerables tendrían más acceso a esta terapia.
Hepatitis C Drug’s Lower Cost Paves Way For Medicaid, Prisons To Expand Treatment
The drug, sold under the name Mavyret, can cure all six genetic types of the liver disease in eight weeks at a cost of $26,400, well below other options.
Do Pharma’s Claims On Drug Prices Pass The Smell Test? We Found 5 Stinkers.
Drug companies are in the midst of a glossy publicity campaign to stop attempts to control rising pharma costs. But the devil is in the details.
Pocos se benefician con las nuevas drogas anti colesterol por el gran gasto de bolsillo
Una nueva generación de drogas podría ayudar a millones a bajar los niveles de colesterol malo. Pero el proceso para lograr una receta y el alto costo para el paciente están limitando su uso.
Absent Federal Action, States Take The Lead On Curbing Drug Costs
Congress has yet to take substantive action on this growing consumer concern, but a number of states are flexing their cost-control muscle.
Out-Of-Pocket Costs Often Keep Pricey New Cholesterol Drugs Out Of Reach, Study Finds
Research published this week by JAMA Cardiology analyzed pharmacy claims data related to a new class of cholesterol-lowering drugs.
Right After Trump Blamed High Drug Prices On Campaign Cash, Drugmakers Gave More
At a political rally in March, President Donald Trump said drug prices are “outrageous” and blamed campaign contributions. Drugmakers funneled nearly $280,000 to Congress the very next day.
Everyone Says We Must Control Exorbitant Drug Prices. So, Why Don’t We?
Any momentum to address prescription drug costs has been lost amid rancorous debates over replacing Obamacare and stalled by roadblocks erected via lobbying and industry cash.
Without Price Breaks, Rural Hospitals Struggle To Stock Costly, Lifesaving Drugs
A federal drug program blocks rural hospitals from getting discounts on rare-disease drugs, forcing staff to cut back on supplies of lifesaving medicines.
FDA Moves To Guard Against Abuse Of ‘Orphan Drug’ Program
Following a KHN investigation, the Food and Drug Administration has moved to speed up approvals of “orphan drugs” while closing a loophole that allowed drugmakers to skip pediatric testing.
